This article is more than 5 years old. Information may no longer be current.
Managing Hepatitis C Virus: Pharmacoeconomic and Patient Outcomes Considerations
Click Here to Manage Email Alerts
Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Approximately 75% to 85% of HCV-infected persons will progress to chronic HCV infection and are at risk for the development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma. Approximately 3.2 million persons in the United States are chronically infected today. HCV-associated disease represents the leading indication in the United States for liver transplantation and the leading cause of hepatocellular cancer. The rapid evolution of therapeutic choices in HCV presents opportunities and substantial challenges to physicians, pharmacy directors, medical directors, and other health plan decision makers. In light of evidence for the superior efficacy and adverse effect profiles of new and emerging therapies, health care professionals must select patients for treatment based on a thorough understanding of the economic, clinical, and societal ramifications of their decisions. This activity will help health care professionals implement practice changes and policies to improve patient outcomes in a cost-effective manner.
Learning Objectives:
After completing this activity, participants should be able to:
- Review the adherence profiles, safety profiles and effectiveness of established and new pharmacotherapies for the treatment of HCV.
- Assess the impact of inadequate disease control on the clinical and economic burden of HCV.
- Apply clinical evidence and cost-effectiveness data relevant to managed care decision making on new HCV therapies.
- Incorporate institutional strategies that facilitate the appropriate use of newer and emerging HCV therapies.
- Review the extrahepatic manifestations of HCV and their impact on clinical and economic outcome.
Click here to see the Education Lab Activity.
Overview
Author(s)/Faculty: Zobair M. Younossi, MD, MPH; H. Eric Cannon, PharmD, FAMCP
Source: Healio Gastroenterology Education Lab
Type: Multimedia
Articles/Items: 3
Release Date: 12/31/2015
Expiration Date: 12/30/2016
Credit Type: CME/CPE
Number of Credits: 1
Cost: Free
Provider: Vindico Medical Education
CME Information
Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by educational grants from AbbVie and Bristol-Myers Squibb.
Target Audience: The intended audience for this activity is pharmacy directors, medical directors, and other health plan decision makers whose patient population includes individuals infected with HCV.